Functional MRI and CT biomarkers in oncology

被引:21
|
作者
Winfield, J. M. [1 ,2 ,3 ,4 ]
Payne, G. S. [1 ,2 ]
deSouza, N. M. [1 ,2 ]
机构
[1] Inst Canc Res, CRUK Imaging Ctr, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, MRI Unit, Sutton SM2 5PT, Surrey, England
[4] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England
基金
英国医学研究理事会;
关键词
MRI; CT; Biomarker; Oncology; APPARENT DIFFUSION-COEFFICIENT; MAGNETIC-RESONANCE-SPECTROSCOPY; CELL LUNG-CANCER; CONTRAST-ENHANCED MRI; IN-VIVO; PROSTATE-CANCER; BREAST-CANCER; VESSEL SIZE; DCE-MRI; IMAGING BIOMARKERS;
D O I
10.1007/s00259-014-2979-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging biomarkers derived from MRI or CT describe functional properties of tumours and normal tissues. They are finding increasing numbers of applications in diagnosis, monitoring of response to treatment and assessment of progression or recurrence. Imaging biomarkers also provide scope for assessment of heterogeneity within and between lesions. A wide variety of functional parameters have been investigated for use as biomarkers in oncology. Some imaging techniques are used routinely in clinical applications while others are currently restricted to clinical trials or preclinical studies. Apparent diffusion coefficient, magnetization transfer ratio and native T-1 relaxation time provide information about structure and organization of tissues. Vascular properties may be described using parameters derived from dynamic contrast-enhanced MRI, dynamic contrast-enhanced CT, transverse relaxation rate (R-2*), vessel size index and relative blood volume, while magnetic resonance spectroscopy may be used to probe the metabolic profile of tumours. This review describes the mechanisms of contrast underpinning each technique and the technical requirements for robust and reproducible imaging. The current status of each biomarker is described in terms of its validation, qualification and clinical applications, followed by a discussion of the current limitations and future perspectives.
引用
收藏
页码:562 / 578
页数:17
相关论文
共 50 条
  • [1] Functional MRI and CT biomarkers in oncology
    J. M. Winfield
    G. S. Payne
    N. M. deSouza
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 562 - 578
  • [2] Imaging biomarkers in oncology: Basics and application to MRI
    Dregely, Isabel
    Prezzi, Davide
    Kelly-Morland, Christian
    Roccia, Elisa
    Neji, Radhouene
    Goh, Vicky
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2018, 48 (01) : 13 - 26
  • [3] Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials
    Shukla-Dave, Amita
    Obuchowski, Nancy A.
    Chenevert, Thomas L.
    Jambawalikar, Sachin
    Schwartz, Lawrence H.
    Malyarenko, Dariya
    Huang, Wei
    Noworolski, Susan M.
    Young, Robert J.
    Shiroishi, Mark S.
    Kim, Harrison
    Coolens, Catherine
    Laue, Hendrik
    Chung, Caroline
    Rosen, Mark
    Boss, Michael
    Jackson, Edward F.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2019, 49 (07) : E101 - E121
  • [4] New developments in oncology MRI
    de Bazelaire, C.
    Chapellier, M.
    Pluvinage, A.
    Scemama, A.
    Pilehvari, F.
    Bourrier, P.
    Frija, J.
    de Kerviler, E.
    ONCOLOGIE, 2010, 12 (03) : 187 - 196
  • [5] MRI biomarkers in neuro-oncology
    Smits, Marion
    NATURE REVIEWS NEUROLOGY, 2021, 17 (08) : 486 - 500
  • [6] Serum efficacy biomarkers for oncology
    Linder, Stig
    Alaiya, Ayodele
    BIOMARKERS IN MEDICINE, 2009, 3 (01) : 47 - 54
  • [7] Imaging biomarkers in prostate cancer: role of PET/CT and MRI
    Picchio, M.
    Mapelli, P.
    Panebianco, V.
    Castellucci, P.
    Incerti, E.
    Briganti, A.
    Gandaglia, G.
    Kirienko, M.
    Barchetti, F.
    Nanni, C.
    Montorsi, F.
    Gianolli, L.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (04) : 644 - 655
  • [8] Imaging biomarkers in prostate cancer: role of PET/CT and MRI
    M. Picchio
    P. Mapelli
    V. Panebianco
    P. Castellucci
    E. Incerti
    A. Briganti
    G. Gandaglia
    M. Kirienko
    F. Barchetti
    C. Nanni
    F. Montorsi
    L. Gianolli
    S. Fanti
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 644 - 655
  • [9] CT and MRI imaging in tumoral angiogenesis
    de Bazelaire, C.
    Calmon, R.
    Chapellier, M.
    Pluvinage, A.
    Frija, J.
    de Kerviler, E.
    BULLETIN DU CANCER, 2010, 97 (01) : 79 - 90
  • [10] PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations
    Mayerhoefer, Marius E.
    Prosch, Helmut
    Beer, Lucian
    Tamandl, Dietmar
    Beyer, Thomas
    Hoeller, Christoph
    Berzaczy, Dominik
    Raderer, Markus
    Preusser, Matthias
    Hochmair, Maximilian
    Kiesewetter, Barbara
    Scheuba, Christian
    Ba-Ssalamah, Ahmed
    Karanikas, Georgios
    Kesselbacher, Julia
    Prager, Gerald
    Dieckmann, Karin
    Polterauer, Stephan
    Weber, Michael
    Rausch, Ivo
    Brauner, Bernhard
    Eidherr, Harald
    Wadsak, Wolfgang
    Haug, Alexander R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (01) : 51 - 60